FreedomWorks Originals provides you entertainment and education to help you better understand economics, the workings of government, and our insight into the most important debates facing our nation today. Watch and subscribe today!
Shortly before Christmas, with no chance for debate or amendments, Congress very nearly slipped a major change in health care law into the year-end government spending bill. Like most such travesties, the effort was bipartisan, written largely behind closed doors, and not open for amendment or debate. Thankfully, this effort failed at the 11th hour, and the language was left out of the bill.
FreedomWorks’ activist-chosen dumpster fire of the month for May 2019 is the Transparent Drug Pricing Act, S. 977. Introduced by Rep. Rick Scott (R-FL), this is yet another proposal targeted at reducing prescription drug prices in America based on the faulty logic of international price controls. Among other substantive changes to public health regulations, S. 977 would mandate that U.S. prescription drug prices “may not exceed the lowest retail list price for the drug among Canada, France, the United Kingdom, Japan, or Germany.”
Many conservatives and right-of-center political analysts are rightly upset about Health and Human Service Secretary Alex Azar’s proposal to tie drug prices in the United States to those in foreign nations. Such a proposal would make our healthcare system dependent on the whims of nations that subscribe to command and control economic models. There is also the stark reality that imposing price controls does not fix any underlying issues that caused prices to be high in the first place.
Almost all Americans want lower price prescription drugs, and it is indefensible that American consumers often have to pay higher prices than customers in developed nations around the world. This is especially intolerable given that most of the wonder drugs of recent years and decades that we pay more for have been developed on these shores.